Nicox makes changes to board
pharmafile | August 13, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Adrienne Graves, Luzi von Bidder, NicOx
French ophthalmic firm Nicox has confirmed that Dr Adrienne Graves and Luzi von Bidder will be joining its board of directors.
Graves (pictured) and von Bidder will replace Vaughn Kailian, who has been at Nicox since 2001, and Vince Anido.
Kailian decided to step down from the firm with effect from August citing personal reasons. Anido who joined in June 2013 is also stepping down the same month due to his increasing responsibilities at Aerie Pharmaceuticals.
Graves was president and chief executive of Santen, the US arm of Japan’s largest ophthalmic pharma company from 2002 to 2010. Prior to joining Santen, Graves spent nine years with Alcon Laboratories progressing through various roles, including director of International Ophthalmology.
von Bidder was until recently chairman of the Swiss-listed company Acino Holding, and is currently on the board of several other private healthcare companies, including Ferring and Solvias. Prior to joining Acino he served as chairman and chief executive Novartis Ophthalmics, a subsidiary of the Swiss arm of Novartis where he also served as a member of its executive committee.
Nicox also intends to appoint Les Kaplan to its board, who is the executive chairman of Aciex Therapeutics, and former executive VP and president of R&D at Allergan.
Michele Garufi who is Nicox’s chairman and chief executive, says: “We are pleased to nominate to our board three senior executives with a wealth of knowledge of the ophthalmology business.”
Related Content
NicOx to halve HQ workforce
French pharmaceutical company NicOx is to halve the workforce at its Sophia Antipolis headquarters and …
Pfizer plant cleared by FDA to make NicOx drug
Pfizer subsidiary Capsugel has won approval from the US Food and Drug Administration for a …
